Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sennoside A is a natural **dianthrone glycoside** derived mainly from medicinal plants such as Senna and Rhubarb. It is the principal active constituent of several traditional herbal remedies and is chiefly recognized as an **irritant laxative**. Sennoside A acts principally by stimulating colonic motility through direct irritation of the intestinal mucosa, which results in increased peristalsis and bowel evacuation. Beyond its established use for constipation, sennoside A exhibits diverse pharmacological actions including **anti-obesity, hypoglycemic, hepatoprotective, anti-inflammatory, anti-fibrotic, anti-tumor, antibacterial, antifungal, antiviral, and anti-neurodegenerative effects**. Its molecular formula is C42H38O20 with a molecular weight of 862.7 and low water solubility. Sennoside A is also incorporated as an active ingredient in various health supplements and weight-loss products, predominantly in Asia. Long-term or high-dose use has been associated with risks such as melanosis coli and possible carcinogenesis. Sennoside A has poor bioavailability and is metabolized by gut microbiota, which transform it to active aglycone derivatives exerting the laxative effect[1][6][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sennoside a.